August 25, 2017 06:20 AM EDT

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

John Carroll

Editor & Founder

A day after Kyowa Hakko Kirin and Ultragenyx filed their application to sell burosumab, the Japanese pharma company is following up with the news that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

Af­ter a long clin­i­cal odyssey, the FDA tapped this PhI­II an­ti-CCR4 as a ‘break­through’ lym­phoma drug

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A